123 related articles for article (PubMed ID: 10658443)
1. [Increasing transcutaneous PO2 in arteriopathies during treatment with PGE1 alpha-cyclodextrin].
Belcaro G; Cesarone MR
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):37-43. PubMed ID: 10658443
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of costs and results of prostaglandin (PGE1 alpha-cyclodestrin) therapy of peripheral arterial diseases].
Bucci M; Iacobitti P; Laurora G; Cesarone MR
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):9-15. PubMed ID: 10658439
[TBL] [Abstract][Full Text] [Related]
3. [Reduction of cardiovascular morbidity/mortality in arteriopathies treated ith PGE1 alpha-cyclodextrin].
Belcaro G; Bucci M; Cesarone MR; Incandela L; De Sanctis MT
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):51-4. PubMed ID: 10658445
[TBL] [Abstract][Full Text] [Related]
4. ["Responders and non-responders" to PGE1 and alpha-cyclodextrin].
De Sanctis MT; Incandela L; Iacobitti P
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):31-6. PubMed ID: 10658442
[TBL] [Abstract][Full Text] [Related]
5. [European trial of PGE1 alpha cyclodextrin. Short-term vs. long-term therapy in intermittent claudication].
Laurora G; Corsi M; Bucci M; Cesarone MR; Belcaro G; Dugall M
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):21-9. PubMed ID: 10658441
[TBL] [Abstract][Full Text] [Related]
6. [Circadian variations of cutaneous blood flow in normal subjects and in patients with peripheral arteriopathies. Effect of PGE1 and alpha-cyclodextrin].
Laurora G; Belcaro G
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):45-9. PubMed ID: 10658444
[TBL] [Abstract][Full Text] [Related]
7. [Cardiovascular morbidity/mortality modified by the use of FGE1 alpha-cyclodextran and calcium heparin in patients with severe vascular diseases].
Belcaro G; Cesarone MR; Bucci M; Iacobitti P; Dugall M
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):55-8. PubMed ID: 10658446
[TBL] [Abstract][Full Text] [Related]
8. [Intra-arterial infusion of PGE1 alpha cyclodextrin].
Laurora G; Cesarone MR; Belcaro G; Incandela L; De Sanctis MT; Fascetti E; D'Archivio C
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):17-20. PubMed ID: 10658440
[TBL] [Abstract][Full Text] [Related]
9. [Global analysis of data from studies with PDE1 alpha-cyslodextrin].
Laurora G; Belcaro G; Cesarone MR; Incandela L; De Sanctis MT; Dugall M
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):65-8. PubMed ID: 10658448
[TBL] [Abstract][Full Text] [Related]
10. [Intramuscular injections of PGE1 in patients with severe claudication].
Corsi M; Laurora G; Cesarone MR
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):59-63. PubMed ID: 10658447
[TBL] [Abstract][Full Text] [Related]
11. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
Mangiafico RA; Malatino LS; Santonocito M; Messina R; Attinà T; Dell'Arte S; Sarnataro F
Int J Clin Pharmacol Ther; 1999 Jul; 37(7):347-51. PubMed ID: 10442509
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of severe intermittent claudication: ORACLE-PGE1 short term study. A randomised 40-week study. Evaluation of efficacy and costs].
Cesarone MR; Belcaro G; Nicolaides AN; Griffin M; Geroulakos G; Ramaswami G; Cazaubon M; Barsotti A; Vasdekis S; Christopoulos D; Agus G; Bavera P; Mondani P; Ippolito E; Flenda F
Minerva Cardioangiol; 2002 Dec; 50(6):683-90. PubMed ID: 12473989
[TBL] [Abstract][Full Text] [Related]
13. Red cell deformability in patients with chronic atheromatous ischemia of the legs.
Drozdz W; Panek J; Lejman W
Med Sci Monit; 2001; 7(5):933-9. PubMed ID: 11535938
[TBL] [Abstract][Full Text] [Related]
14. Treatment of severe intermittent claudication with PGE1--a short-term vs a long-term infusion plan--a 20 week, European randomized trial--analysis of efficacy and costs.
Belcaro G; Laurora G; Nicolaides AN; Agus G; Cesarone MR; DeSanctis MT; Incandela L; Ricci A; Cazaubon M; Ippolito E; Barsotti A; Vasdekis S; Ledda A; Iacobitti P; Christopoulos D; Errichi BM; Helmis H; Cornelli U; Ramaswami G; Bucci M; Ferrari PG; Corsi M; Pomante P; Mezzanotte L; Geroulakos G
Angiology; 1998 Nov; 49(11):885-94; discussion 895. PubMed ID: 9822044
[TBL] [Abstract][Full Text] [Related]
15. PGE(1) treatment of severe intermittent claudication (short-term versus long-term, associated with exercise)--efficacy and costs in a 20-week, randomized trial.
Belcaro G; Nicolaides AN; Agus G; Cesarone MR; Geroulakos G; Pellegrini L; De Sanctis MT; Incandela L; Ricci A; Mondani P; De Angelis R; Ippolito E; Barsotti A; Vasdekis S; Ledda A; Christopoulos D; Errichi BM; Helmis H; Cornelli U; Ramaswami G; Dugall M; Bucci M; Martines G; Ferrari PG; Corsi M; Di Francescantonio D
Angiology; 2000 Aug; 51(8 Pt 2):S15-26. PubMed ID: 10959507
[TBL] [Abstract][Full Text] [Related]
16. [Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities].
Weiss T; Griesshaber J; Rogatti W; Kistner O; Hsu E; Jansen T; Diehm C
Vasa Suppl; 1991; 33():341-2. PubMed ID: 1788749
[TBL] [Abstract][Full Text] [Related]
17. [Severe intermittent claudication: PGE1 treatment. A 40-week registry, efficacy and costs].
Luzzi R; Belcaro G; Ippolito E; Dugall M; Cesarone MR; Scoccianti M; Errichi BM; Pellegrini L; Ciammaichella G; Ledda A; Ricci A; Cornelli U; Feragalli B; Hosoi M; Corsi M; Simeone E; Agus GB
Minerva Cardioangiol; 2012 Aug; 60(4):405-13. PubMed ID: 22858918
[TBL] [Abstract][Full Text] [Related]
18. [Value of transcutaneous staged dynamic oximetry of stage II arteritis of the leg].
Grard C; Desmytterre J; Vinckier L; Hatron PY; Roux JP; Warembourg H; Devulder B
Arch Mal Coeur Vaiss; 1990 Mar; 83 Spec No 2():51-7. PubMed ID: 2111687
[TBL] [Abstract][Full Text] [Related]
19. Short-range intermittent claudication and rest pain: microcirculatory effects of pentoxifylline in a randomized, controlled trial.
Incandela L; De Sanctis MT; Cesarone MR; Belcaro G; Nicolaides AN; Geroulakos G; Ramaswami G
Angiology; 2002; 53 Suppl 1():S27-30. PubMed ID: 11865832
[TBL] [Abstract][Full Text] [Related]
20. Nomograms used to define the short-term treatment with PGE(1) in patients with intermittent claudication and critical ischemia. The ORACL.E (Occlusion Revascularization in the Atherosclerotic Critical Limb) Study Group. The European Study.
Belcaro G; Nicolaides AN; Cipollone G; Laurora G; Incandela L; Cazaubon M; Barsotti A; Ledda A; Errichi BM; Cornelli U; Dugall M; Corsi M; Mezzanotte L; Geroulakos G; Fisher C; Szendro G; Simeone E; Cesarone MR; Bucci M; Agus G; De Sanctis MT; Ricci A; Ippolito E; Vasdekis S; Christopoulos D; Helmis H
Angiology; 2000 Aug; 51(8 Pt 2):S3-13; discussion S14. PubMed ID: 10959506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
